BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1163 related articles for article (PubMed ID: 19531404)

  • 21. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates.
    Lazarovici TS; Mesilaty-Gross S; Vered I; Pariente C; Kanety H; Givol N; Yahalom R; Taicher S; Yarom N
    J Oral Maxillofac Surg; 2010 Sep; 68(9):2241-7. PubMed ID: 20728033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects.
    Ficarra G; Beninati F
    Head Neck Pathol; 2007 Dec; 1(2):132-40. PubMed ID: 20614264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positron-emission tomography imaging in the diagnosis of bisphosphonate-related osteonecrosis of the jaw.
    Wilde F; Steinhoff K; Frerich B; Schulz T; Winter K; Hemprich A; Sabri O; Kluge R
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Mar; 107(3):412-9. PubMed ID: 19121962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate.
    Ulmner M; Jarnbring F; Törring O
    J Oral Maxillofac Surg; 2014 Jan; 72(1):76-82. PubMed ID: 23992777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Diphosphonates can cause necrosis of the jaw. Patients with malignant skeletal diseases are at risk].
    Jarnbring F; Ulmner M; Blomlöf J; Ljungman P
    Lakartidningen; 2006 May 31-Jun 6; 103(21-22):1741-3. PubMed ID: 16826719
    [No Abstract]   [Full Text] [Related]  

  • 27. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients.
    Lazarovici TS; Yahalom R; Taicher S; Elad S; Hardan I; Yarom N
    J Oral Maxillofac Surg; 2009 Apr; 67(4):850-5. PubMed ID: 19304045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results.
    Morris PG; Poznak CV; Modi S; Mak AF; Patil S; Larson S; Hudis CA; Divgi C; Grewal RK
    Clin Breast Cancer; 2010 Feb; 10(1):33-9. PubMed ID: 20133256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases.
    Grant BT; Amenedo C; Freeman K; Kraut RA
    J Oral Maxillofac Surg; 2008 Feb; 66(2):223-30. PubMed ID: 18201600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
    Abu-Id MH; Warnke PH; Gottschalk J; Springer I; Wiltfang J; Acil Y; Russo PA; Kreusch T
    J Craniomaxillofac Surg; 2008 Mar; 36(2):95-103. PubMed ID: 18234504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Encounter of cancer cells with bone. Present status and problems in occurrence of bisphosphonate-related osteonecrosis of the jaws].
    Urade M
    Clin Calcium; 2011 Mar; 21(3):420-7. PubMed ID: 21358064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws.
    Dodson TB
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):44-52. PubMed ID: 19371814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
    Kunchur R; Need A; Hughes T; Goss A
    J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imaging findings in bisphosphonate-related osteonecrosis of jaws.
    Arce K; Assael LA; Weissman JL; Markiewicz MR
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):75-84. PubMed ID: 19371818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
    Wang EP; Kaban LB; Strewler GJ; Raje N; Troulis MJ
    J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update.
    Bagan J; Scully C; Sabater V; Jimenez Y
    Oral Oncol; 2009 Jul; 45(7):551-4. PubMed ID: 19251474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
    Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G
    Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis?
    Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Otto S; Pautke C
    J Oral Maxillofac Surg; 2014 May; 72(5):903-10. PubMed ID: 24485975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
    Murad OM; Arora S; Farag AF; Guber HA
    Endocr Pract; 2007; 13(3):232-8. PubMed ID: 17599853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
    Otto S; Schreyer C; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum S; Pautke C
    J Craniomaxillofac Surg; 2012 Jun; 40(4):303-9. PubMed ID: 21676622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.